Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
KECK KIM reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Kim Keck received an equity grant that increases her direct ownership stake. She was awarded 41,096 shares of Class A Common Stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan, bringing her direct holdings to 102,597 shares. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, as long as she continues serving on the board.
Evolent Health, Inc. director Jill D. Smith reported an equity compensation grant. She acquired 41,096 shares of Class A Common Stock in the form of restricted stock units granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
The securities vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting, contingent on her continued service through the vesting date. Following this award, Smith holds 64,233 shares of Evolent Health common stock directly.
Springstubb Brendan B reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Brendan B. Springstubb received a grant of 41,096 shares of Class A Common Stock in the form of restricted stock units at a price of $0.00 per share. Following this equity award, he holds 99,917 shares directly. The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and will vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, subject to his continued service.
Barbarosh Craig A. reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Craig A. Barbarosh received an equity grant of 41,096 restricted stock units of Class A Common Stock. The award was made at no cash cost to him as part of Evolent Health’s 2015 Omnibus Incentive Compensation Plan. These units are scheduled to vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, contingent on his continued board service. Following this grant, he directly holds 95,031 shares of Class A Common Stock.
Evolent Health, Inc. reported the results of its 2026 annual stockholder meeting held on June 4, 2026. Stockholders elected ten director nominees to one-year terms ending at the 2027 annual meeting. Each nominee received significantly more votes “for” than “against,” with substantial broker non-votes recorded.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. An advisory vote approved 2025 compensation for named executive officers, and investors approved an amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, supporting the company’s executive pay and equity incentive framework.
Evolent Health, Inc. reported first-quarter 2026 revenue of $496.2 million, slightly above $483.6 million a year earlier, reflecting growth across Medicaid, Medicare and commercial lines. The company recorded an operating loss of $10.6 million and a net loss of $26.6 million, a marked improvement from a $72.3 million loss a year ago, with loss per share narrowing to $0.24 from $0.63. Cash and restricted cash totaled $168.7 million, while long-term debt stood at $973.5 million, plus substantial term loans and revolving borrowings under its credit facilities. Management states current liquidity, including $142.0 million of unrestricted cash, is sufficient to cover at least the next twelve months. Reserves for claims and performance-based arrangements rose to $232.0 million, highlighting the scale of risk-sharing contracts in its value-based care model.
Evolent Health, Inc. reported first quarter 2026 revenue of $496.2 million, slightly above $483.6 million a year ago, as demand for its complex specialty care solutions remained strong. Net loss attributable to common shareholders narrowed to $26.6 million from $72.3 million, with loss per share improving to $(0.24) from $(0.63).
Profitability metrics weakened on an adjusted basis. Adjusted EBITDA declined to $22.1 million from $36.9 million and adjusted income swung to a $2.3 million loss from $7.4 million of income, reflecting higher medical costs. The medical expense ratio rose to 93.3%, indicating a larger share of revenue flowing to medical claims.
The company highlighted two new revenue agreements, including an imaging contract covering about 4.5 million lives and a Performance Suite expansion expected to generate over $200 million in annual revenue starting in the third quarter, subject to regulatory approvals. Evolent reiterated full-year 2026 guidance for revenue of $2.4–$2.6 billion and adjusted EBITDA of $110–$140 million. Cash and cash equivalents were $142.0 million as of March 31, 2026.
Evolent Health, Inc. has issued its 2026 proxy statement for a fully virtual annual meeting on June 4, 2026. Stockholders will vote on electing ten directors, ratifying Deloitte & Touche LLP as auditor, approving 2025 executive pay on an advisory basis, and amending the 2015 Omnibus Incentive Plan to increase shares available for future awards.
For 2025, Evolent reports revenue of $1,876.2 million, average unique members of 40.4 million, and Adjusted EBITDA of $151.2 million, while noting a stock price decline amid industry headwinds and policy changes. The company highlights strong new business wins, a refinancing of 2025 convertible notes that pushes the next major debt maturity to December 2029, and the sale of Evolent Care Partners to reduce senior debt and interest expense.
Governance updates include an Independent Board Chair, ongoing board refresh with three new independent directors in 2025, and fully independent key committees. The executive compensation program emphasizes pay-for-performance, mixes short- and long-term incentives, and uses PSUs tied to relative total shareholder return, with negative discretion applied to 2025 incentives to reflect share price performance.
Evolent Health Inc: The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report disaggregated holdings and that Vanguard's reported beneficial ownership of Evolent Health common stock is 0 shares (0%) as reflected in the filing dated 03/13/2026 and signed 03/26/2026.